Advertisement

Topics

Zogenix to Release Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9

20:00 EDT 1 Aug 2016 | Globe Newswire

EMERYVILLE, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30, 2016 after the market close, and will host a corporate update conference call and webcast on Tuesday, August 9th, at 4:30 PM Eastern Time.

Tuesday, August 9 @ 4:30 PM Eastern Time/1:30 PM Pacific Time
Toll Free:888-378-0320
International:719-325-2354
Conference ID:3485336
Webcast:http://public.viavid.com/index.php?id=120393
  


Replays, available through August 23:
Domestic:877-870-5176
International:858-384-5517
Replay PIN:3485336
  

About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.

For more information, visit www.zogenix.com.

 

CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Zogenix to Release Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...